Neurocrine Biosciences, Inc. (NBIX)
157.21
-1.21
(-0.76%)
USD |
NASDAQ |
May 18, 16:00
158.00
+0.79
(+0.50%)
After-Hours: 20:00
Neurocrine Biosciences Research and Development Expense (Quarterly) : 296.20M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Soleno Therapeutics, Inc. | 11.27M |
| Biogen, Inc. | 471.10M |
| Nuvalent, Inc. | 83.61M |
| Marker Therapeutics, Inc. | 2.843M |
| Denali Therapeutics, Inc. | 103.85M |